Ingen Technologies, Inc. (IGNT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ingen Technologies, Inc. (IGNT) trades at $0.00005 with AI Score 49/100 (Grade C). Ingen Technologies, Inc. specializes in manufacturing medical devices for the respiratory industry, particularly for patients with chronic obstructive pulmonary disease (COPD). Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for IGNT: IGNT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IGNT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IGNT: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Ingen Technologies, Inc. (IGNT) Healthcare & Pipeline Overview
Ingen Technologies, Inc. manufactures and distributes respiratory medical devices, including oxygen flow meters and nasal cannulas, primarily serving patients with COPD. The company's focus on pneumatic metering devices and specialized nasal cannula technology positions it within a niche segment of the broader medical device market, characterized by increasing demand for home healthcare solutions.
What Is the Investment Thesis for IGNT?
Ingen Technologies, Inc. presents a focused investment opportunity within the respiratory medical device sector. The company's specialization in oxygen flow meters and nasal cannulas for COPD patients positions it to capitalize on the growing demand for home healthcare solutions. A key value driver is the company's proprietary Oxyview technology, which offers precise oxygen flow monitoring. However, potential investors may want to evaluate the company's negative P/E ratio of -0.05 and a significant negative profit margin of -7460.4%. While the gross margin is a high 95.7%, profitability remains a concern. Growth catalysts include expanding distribution networks and potential partnerships to reach a broader patient base. The investment thesis hinges on Ingen's ability to achieve profitability through increased sales volume and efficient cost management.
Based on FMP financials and quantitative analysis
IGNT Key Highlights
Ingen Technologies operates in the medical device industry, focusing on respiratory care products.
- The company's primary products include oxygen flow meters and nasal cannulas under the Oxyview and Smart Nasal Cannula trademarks.
- Ingen Technologies has a high gross margin of 95.7%, indicating efficient production processes.
- The company's P/E ratio is -0.05, reflecting current losses.
- Ingen Technologies serves patients suffering from chronic obstructive pulmonary disease (COPD).
Who Are IGNT's Competitors?
IGNT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IGNT's Key Strengths?
Specialized product line focused on respiratory care.
- Proprietary Oxyview technology for accurate oxygen flow monitoring.
- Established presence in the respiratory medical device market.
- High gross margin of 95.7%.
What Are IGNT's Weaknesses?
Negative P/E ratio of -0.05, indicating current losses.
- High negative profit margin of -7460.4%.
- Limited product diversification.
- Dependence on the respiratory care market.
What Could Drive IGNT Stock Higher?
Potential partnerships with home healthcare providers to expand distribution.
- Development and launch of new respiratory devices.
- Increasing demand for home healthcare solutions for COPD patients.
- Expansion of the Oxyview product line.
- Integration of devices with telehealth platforms.
What Are the Key Risks for IGNT?
Competition from larger medical device manufacturers.
- Regulatory changes affecting the medical device industry.
- Economic downturn impacting healthcare spending.
- Technological advancements rendering existing products obsolete.
- The company's negative P/E ratio and high negative profit margin.
What Are the Growth Opportunities for IGNT?
- Expansion of Product Line: Ingen Technologies can expand its product line to include additional respiratory devices and accessories, such as nebulizers, ventilators, and sleep apnea devices. This would allow the company to cater to a broader range of respiratory conditions and increase its market share. The global market for respiratory devices is projected to reach $35 billion by 2028, providing a significant opportunity for growth. Timeline: 2-3 years.
- Strategic Partnerships: Ingen Technologies can form strategic partnerships with home healthcare providers, hospitals, and durable medical equipment (DME) suppliers to expand its distribution network and reach a larger patient base. These partnerships can provide access to established sales channels and enhance the company's brand recognition. The market for home healthcare services is expected to grow at a rate of 8% annually, creating a favorable environment for partnerships. Timeline: 1-2 years.
- Geographic Expansion: Ingen Technologies can expand its geographic presence beyond the United States to international markets, such as Europe and Asia, where there is a growing demand for respiratory care products. This would require obtaining regulatory approvals in each target market and establishing distribution channels. The global market for respiratory devices is expected to grow at a CAGR of 6% over the next five years, driven by increasing healthcare spending in emerging markets. Timeline: 3-5 years.
- Telehealth Integration: Ingen Technologies can integrate its devices with telehealth platforms to enable remote patient monitoring and management. This would allow healthcare providers to track patients' oxygen levels and respiratory function remotely, improving patient outcomes and reducing healthcare costs. The telehealth market is projected to reach $175 billion by 2026, creating a significant opportunity for Ingen Technologies to leverage its technology. Timeline: 1-2 years.
- Focus on Innovation: Ingen Technologies can invest in research and development to develop innovative respiratory devices and technologies that address unmet needs in the market. This could include developing more advanced oxygen delivery systems, wearable respiratory sensors, and AI-powered respiratory monitoring tools. The market for innovative medical devices is growing rapidly, driven by increasing demand for personalized and data-driven healthcare solutions. Timeline: Ongoing.
What Are IGNT's Competitive Advantages?
- Specialized product line focused on respiratory care.
- Proprietary Oxyview technology for accurate oxygen flow monitoring.
- Established presence in the respiratory medical device market.
- Brand recognition for Oxyview and Smart Nasal Cannula products.
What Does IGNT Do?
Founded in 1999 and based in Riverside, California, Ingen Technologies, Inc. operates as a medical device manufacturing company focused on the respiratory industry. The company develops, manufactures, and markets medical equipment designed for patients suffering from chronic obstructive pulmonary disease (COPD). Ingen's core product offerings include oxygen flow meters and nasal cannulas, marketed under the Oxyview and Smart Nasal Cannula trademarks. The Oxyview device is a pneumatic metering device that displays and confirms the oxygen flow rate near the patient, ensuring accurate and reliable oxygen delivery. The Smart Nasal Cannula is designed to enhance patient comfort and improve oxygen delivery efficiency. Ingen Technologies targets the home healthcare market, providing solutions that enable patients to manage their respiratory conditions effectively outside of a hospital setting. The company's focus on specialized respiratory devices differentiates it from larger medical device manufacturers with broader product portfolios. Ingen Technologies distributes its products primarily within the United States.
What Products and Services Does IGNT Offer?
- Manufactures medical devices for the respiratory industry.
- Produces medical equipment for patients with chronic obstructive pulmonary disease (COPD).
- Offers oxygen flow meters under the Oxyview trademark.
- Provides nasal cannulas under the Smart Nasal Cannula trademark.
- Develops pneumatic metering devices to display and confirm oxygen flow rates.
- Focuses on improving oxygen delivery and patient comfort.
How Does IGNT Make Money?
- Manufactures and sells oxygen flow meters and nasal cannulas.
- Targets patients with chronic obstructive pulmonary disease (COPD).
- Distributes products through medical equipment suppliers and healthcare providers.
- Generates revenue from the sale of its medical devices.
What Industry Does IGNT Operate In?
Ingen Technologies operates within the medical device industry, specifically targeting the respiratory care segment. This segment is driven by the increasing prevalence of respiratory diseases such as COPD, and the growing demand for home healthcare solutions. The market is competitive, with established players like AFIB (Acutus Medical, Inc.) and ALST (Allstar Healthcare, Inc.) offering a range of respiratory devices. Ingen Technologies differentiates itself through its focus on specialized oxygen delivery and monitoring devices. The industry is subject to regulatory oversight, requiring companies to obtain approvals for their products. Market trends include the adoption of telehealth and remote patient monitoring, which could create opportunities for Ingen Technologies to integrate its devices with digital health platforms.
Who Are IGNT's Key Customers?
- Patients suffering from chronic obstructive pulmonary disease (COPD).
- Hospitals and clinics providing respiratory care.
- Home healthcare providers.
- Durable medical equipment (DME) suppliers.
Company Profile
Ingen Technologies, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Riverside, US. The company is led by CEO Gary Tilden. IGNT has traded publicly since 1995.
How Ingen Technologies, Inc. Is Valued
Relative to its peer group, IGNT's quantitative score of 49/100 is below the peer average of 65/100.
Key Financial Metrics
Return on equity for Ingen Technologies, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Ingen Technologies, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
IGNT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in its potential growth.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments that could enhance market position.
- Increased media coverage has sparked interest, leading to a more engaged investor base and heightened awareness of Ingen's offerings.
- Strategic partnerships announced recently are seen as a strong move to expand market reach and drive revenue growth.
Bear Case
- Some analysts express concerns about the company's ability to scale operations effectively, which may hinder long-term growth prospects.
- Recent negative sentiment on social platforms reflects worries about competition in the industry, potentially overshadowing Ingen's innovations.
- Market perception remains cautious due to previous financial performance, leading to skepticism about the sustainability of recent buzz.
- Insider selling activity has raised red flags among some investors, prompting fears about potential issues within the management team.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IGNT Latest News
No recent news available for IGNT.
IGNT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IGNT.
Price Targets
Wall Street price target analysis for IGNT.
IGNT MoonshotScore
What does this score mean?
The MoonshotScore rates IGNT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David S. Hanson
CEO
David S. Hanson is the Chief Executive Officer of Ingen Technologies, Inc. His background includes experience in the medical device industry, with a focus on product development and marketing. He has been involved in the development and commercialization of several respiratory care products. His expertise lies in identifying market needs and developing innovative solutions to address them. He has a strong understanding of the regulatory landscape and the challenges of bringing new medical devices to market.
Track Record: Under David S. Hanson's leadership, Ingen Technologies, Inc. has focused on expanding its product line and distribution network. Key milestones include the development and launch of the Smart Nasal Cannula and the expansion of the Oxyview product line. He has focused on improving the company's operational efficiency and reducing costs. However, the company's profitability remains a challenge.
IGNT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ingen Technologies, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet the requirements of higher tiers. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The Unknown disclosure status makes it difficult to assess the company's financial health.
- Low Liquidity: The OTC Other listing and small market cap suggest limited trading volume and wide bid-ask spreads.
- Regulatory Scrutiny: OTC-listed companies are subject to less regulatory oversight than exchange-listed companies.
- Going Concern Risk: Companies on the OTC Other tier may face financial difficulties or be at risk of bankruptcy.
- Price Volatility: Low trading volume can lead to significant price fluctuations.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's revenue and profitability trends.
- Check for any legal or regulatory issues involving the company.
- Monitor the company's trading volume and price volatility.
- Consult with a financial advisor before investing.
- The company has been in operation since 1999.
- The company manufactures and sells medical devices.
- The company has trademarks for its Oxyview and Smart Nasal Cannula products.
- The company has a CEO, David S. Hanson.
- The company is based in the United States.
IGNT Healthcare Stock FAQ
What does the AI Score mean for IGNT?
IGNT holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Ingen Technologies, Inc. specializes in manufacturing medical devices for the respiratory industry, particularly for patients with chronic obstructive pulmonary disease (COPD). Their key products …
What does Ingen Technologies, Inc. do?
Ingen Technologies, Inc. is a medical device manufacturing company specializing in respiratory care products. It primarily manufactures and markets oxygen flow meters under the Oxyview trademark and nasal cannulas under the Smart Nasal Cannula trademark. These devices are designed for patients suffering from chronic obstructive pulmonary disease (COPD), providing solutions for accurate oxygen delivery and patient comfort.
What do analysts say about IGNT stock?
As of 2026-03-17, there is no available analyst coverage for Ingen Technologies, Inc. (IGNT). Given the company's OTC listing and small market capitalization, it is not widely followed by analysts. Key valuation metrics include a negative P/E ratio of -0.05 and a high gross margin of 95.7%.
What are the main risks for IGNT?
The main risks for Ingen Technologies, Inc. include competition from larger medical device manufacturers, regulatory changes affecting the medical device industry, and the potential for an economic downturn impacting healthcare spending. The company's negative P/E ratio and high negative profit margin also pose significant risks. Additionally, technological advancements could render existing products obsolete.
What are the key factors to evaluate for IGNT?
Ingen Technologies, Inc. (IGNT) holds an AI score of 49/100 (low). presents a focused investment opportunity within the respiratory medical device sector. Not financial advice.
How frequently does IGNT data refresh on this page?
IGNT's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IGNT's recent stock price performance?
Ingen Technologies, Inc. (IGNT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product line focused on respiratory care. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IGNT overvalued or undervalued right now?
Ingen Technologies, Inc. (IGNT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research IGNT before investing?
Before investing in Ingen Technologies, Inc. (IGNT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the latest available information.
- OTC market data may be limited or unreliable.
- AI analysis is pending and may provide further insights.